DOCSLIB.ORG

Urinary Tract Infections (Utis) Tests Now Available in the Clinical Summaries of Recent Topical PAID Continued

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MARCH 2011 | VOLUME 4 No. 2 | Quarterly Publication Medical Diagnostic Laboratories, L.L.C. Presorted 2439 Kuser Road First-Class Mail Test Announcement U.S. Postage Research & Development Journal Watch Hamilton, NJ 08690 Urinary Tract Infections (UTIs) Tests now available in the clinical Summaries of recent topical PAID Continued ...................... pg 2 laboratory publications in the medical literature Trenton, NJ Full Article ...................... pg 8 Full Article ...................... pg 9 Permit 348 SM The Laboratorian WHAT’S INSIDE Urinary Tract Infections in Women and Men P2 Urinary Tract Infections (UTIs) Author: Jack H. Mydlo, MD, FACS. Table 1: Other Risk Factors for UTIs. Continued By definition, urine is normally free of bacteria. 1. Frequency of intercourse P3 Urinary Tract Infections (UTIs) Bacteriuria indicates the presence of bacteria in the 2. Use of a diaphragm Continued urine, and this may be asymptomatic or symptomatic. 3. Estrogen deficiency P4 Urinary Tract Infections in Women Urinary tract infections (UTIs) can be classified as 4. Antibiotic usage and Men Continue to their site of origin. They are considered to be the 5. Infants P5 Urinary Tract Infections in Women most common bacterial infection. They are usually and Men Continue Research & Development 6. Pregnant women associated with minimal morbidity. Urinary Tract Infections (UTIs) 7. Elderly P6 Urinary Tract Infections in Women Continued ...................... pg 2 and Men Continue UTIs are considered the most common bacterial 8. Spinal cord injury 9. Indwelling catheters P7 Urinary Tract Infections (UTIs) infection, and accounts for nearly 7 million office Continued Test Announcement visits, 1 million emergency room visits, and 100,000 10. Diabetes Tests now available in the clinical 11. Multiple sclerosis P8 New tests and e-quiz laboratory hospital admissions annually. It increases from 1% Full Article ...................... pg 8 in school aged girls to 4% in young adulthood. It then 12. HIV-AIDS P8 Recent Publications SM increases by 2% for every decade of life. 13. Urologic pathology P9 Journal Watch Journal Watch P10 ClassifiedAd Summaries of recent topical publications About 10% of women will have a UTI in any given The bacteria that causes most urinary tract in the medical literature year. More than half of all women have had at least infections is from E. coli, which is mostly present Full Article ...................... pg 9 The one UTI in their lifetime. One in three women will in the bowel. Other organisms include Proteus, Laboratorian have a UTI by the time they reach 24, compared to Klebsiella, Enteroccocus and Staphylococcus. men, in which UTIs are more common after the age of The female urethra is short, and bacteria usually UPCOMING EVENTS 50, due to bladder outlet obstruction from an enlarged enter it via the ascending route. WorldWide Medical Products, Inc. prostate. It is generally believed that some failure of the 04/1-3 ACOG-OR: Oregon Section Sun River, OR Approximately 5 million physician visits a year are host defense mechanism allows for colonization of Item Number - 71011010 the introitus and vaginal mucosa in women, which due to urinary tract infections, which can cost around 04/13-16 SCOG: 52nd Annual Meeting Powder-Free Latex Gloves is subject to recurrent bacterial infection from Item Number - 71011000 1000/case - $48.95 $1.6 billion annually. of the South Central Obstetrical Item Number - 14001003 Powder-Free Nitrile Gloves outside the urinary tract. While colonized, these & Gynecological Society Small Vaginal Speculum, Indiv. Wrapped 1000/case - $54.95 Symptomatic UTIs are increased among sexually women can experience recurrent UTIs every 6-12 Charlottesville, VA 10/pack - $37.95 active women, delayed post-coital voiding, anatomic months. Although these can be easily treated with urinary tract anomalies, reflux, cystocele, stones and antibiotics, they generally recur within weeks to 04/14-16 NASPAG: The North American Society for Pediatric and bladder diverticula. Other risk factors for UTIs are months. Item Number - 14001004 Continued.............pg 4 Adolescent Gynecology Medium Vaginal Speculum, Indiv. Wrapped summarized in Table 1. (NASPAG) Annual Meeting 10/pack - $39.95 Chicago, IL Item Number - 14001005 Large Vaginal Speculum, Indiv. Wrapped Item Number - 14011002 04/27 NEOG: New England OBGYN 10/pack - $41.95 Exam Table Rolls, Crepe, 21” x 125’, Society, Sturbridge, MA White 12/case - $24.92 Urinary Tract Infections (UTIs) 04/28-29 MWS: Matt Weis Author: David W. Hilbert, Ph.D. Symposium 2011 UTIs are a major source of morbidity and associated the presence of a significant level of bacteria in the St. Louis, MO healthcare costs in the United States (US). Community- urine (i.e. bacteriuria). Guidelines vary, but typically Item Number - 31031000 04/30-05/4 ACOG: National Meeting 4 6 3” Cotton Tipped Applicator acquired UTIs largely affect women of reproductive a pure culture of between 10 -10 colony forming Washington, DC 1000/box - $3.15 age, with 11% of women experiencing one each year, units (CFUs)/milliliter (mL) of urine is indicative of Item Number - 31031001 Item Number - 14011006 one-third of women having one by the age of 26, and a UTI. Patient symptoms are painful, urgent and 05/22-24 CLMA: Clinical Laboratory 6” Cotton Tipped Applicator Exam Table Rolls, Smooth, 21” x 125’, Management Association 1000/box - $4.49 White10/pack - $35.76 60% experiencing at least one during their lifetime [1]. frequent urination, along with malodorous and/ In 1997 these infections resulted in 7 million physician or cloudy urine. Signs of infection include the Think Lab, Baltimore, MD Item Number - 31031005 51/2” Tongue Depressors Sterile 41021159 10x75- Borosilicate Disposable Culture Tubes- 1000/cs 34.50 office visits and 1 million emergency room visits [2]. presence in urine of blood (hematuria) or white 1000/case - $32.95 41021160 12x75- Borosilicate Disposable Culture Tubes- 1000/cs 38.75 Treatment of these infections cost $1.6 billion in 1995 blood cells (pyuria). 41021161 13x100- Borosilicate Disposable Culture Tubes- 1000/cs 49.25 [1], which is the equivalent of $2.2 billion in inflation- 41021164 16x125- Borosilicate Disposable Culture Tubes- 1000/cs 79.50 Item Number - 31031006 Continued.............pg 2 41021165 16x150- Borosilicate Disposable Culture Tubes- 1000/cs 85.50 adjusted 2009 dollars. UTIs are defined clinically by 6” Tongue Depressors Sterile 1000/case - $32.95 866.889.WWMP(9967) • FAX: 609.570.1110 • WWW.WWMPONLINE.COM For information on placing a classified advertisement, please email [email protected]. Laboratorian_April_2011.indd 1 5/10/11 11:23 AM Urinary Tract Infections (UTIs) normally discovered during childhood, and most adults suffering from recurrent infections have anatomically normal urinary tracts. Ultrasound imaging can be performed if the clinician suspects an anatomical OURNAL ATCH etiology in a patient suffering from recurrent UTIs. J W Yasufuku T, Shigemura K, Shirakawa T, Matsumoto M, Nakano Pallett A, Hand K. 2010. Complicated urinary tract infections: Treatment Y, Tanaka K, Arakawa S, Kinoshita S, Kawabata M, Fujisawa practical solutions for the treatment of multiresistant Gram- Community-acquired symptomatic UTIs are treated with empirical M. 2011. Correlation of overexpression of efflux pump genes with negative bacteria. J Antimicrob Chemother. 2010 65:25-33. antimicrobial therapy upon diagnosis. The recommended first-line antibiotic resistance in Escherichia coli Strains clinically isolated (Review) antibiotic therapy for cystitis is either 100 milligrams (mg) of nitrofurantoin from urinary tract infection patients. J Clin Microbiol. 49:189-94. per day for 5 days or 160 mg-800 mg of trimethoprim-sulfamethoxazole Resistance in Gram-negative bacteria has been increasing, (SXT) per day for 3 days. Nitrofurantoin should be avoided if Escherichia coli is one of the most common pathogens in particularly over the last 6 years. This is mainly due to the pyelonephritis is suspected, as this drug only reaches an effective urinary tract infections (UTIs), and antibiotic resistance in E. coli spread of strains producing extended-spectrum β-lactamases Figure 1. Epidemiology of UTIs. UPEC from an environmental concentration in the bladder. SXT should be avoided if resistance in the is becoming a serious problem in treating UTI. Efflux system (ESBLs) such as CTX-M enzymes or AmpC β-lactamases. Many reservoir (1) colonizes the patient GI tract via the oral route (2). area is >20% or if the patient has been treated with this antibiotic in the overexpression is reported to contribute to E. coli resistance of the isolates producing these enzymes are also resistant to UPEC in the GI tract colonizes the rectum and is shed in feces (3), last three months. Fosfomycin (3 gram single dose) can also be used, to several antibiotics. This study investigated the correlation of trimethoprim, quinolones and aminoglycosides, often due to from where it colonizes the vagina and periurethral area (4). UPEC ascends the urethra to the bladder, causing either asymptomatic but some studies suggest it is less effective than nitrofurantoin or SXT. antibiotic susceptibilities with the over expression of the efflux plasmid co-expression of other resistance mechanisms. CTX-M- bacteriuria (ABU) or symptomatic infection (cystitis) (5). In some Although amoxicillin and ampicillin should be avoided due to endemic pump genes such as marA, yhiU, yhiV, and mdfA and with producing Escherichia coli often occurs
Recommended publications
  • 3-Year Results of Transvaginal Cystocele Repair with Transobturator Four-Arm Mesh: a Prospective Study of 105 Patients

    3-Year Results of Transvaginal Cystocele Repair with Transobturator Four-Arm Mesh: a Prospective Study of 105 Patients

    Arab Journal of Urology (2014) 12, 275–284 Arab Journal of Urology (Official Journal of the Arab Association of Urology) www.sciencedirect.com ORIGINAL ARTICLE 3-year results of transvaginal cystocele repair with transobturator four-arm mesh: A prospective study of 105 patients Moez Kdous *, Fethi Zhioua Department of Obstetrics and Gynecology, Aziza Othmana Hospital, Tunis, Tunisia Received 27 January 2014, Received in revised form 1 May 2014, Accepted 24 September 2014 Available online 11 November 2014 KEYWORDS Abstract Objectives: To evaluate the long-term efficacy and safety of transobtura- tor four-arm mesh for treating cystoceles. Genital prolapse; Patients and methods: In this prospective study, 105 patients had a cystocele cor- Cystocele; rected between January 2004 and December 2008. All patients had a symptomatic Transvaginal mesh; cystocele of stage P2 according to the Baden–Walker halfway stratification. We Polypropylene mesh used only the transobturator four-arm mesh kit (SurgimeshÒ, Aspide Medical, France). All surgical procedures were carried out by the same experienced surgeon. ABBREVIATIONS The patients’ characteristics and surgical variables were recorded prospectively. The VAS, visual analogue anatomical outcome, as measured by a physical examination and postoperative scale; stratification of prolapse, and functional outcome, as assessed by a questionnaire TOT, transobturator derived from the French equivalents of the Pelvic Floor Distress Inventory, Pelvic tape; Floor Impact Questionnaire and the Pelvic Organ Prolapse–Urinary Incontinence- TVT, tension-free Sexual Questionnaire, were considered as the primary outcome measures. Peri- vaginal tape; and postoperative complications constituted the secondary outcome measures. TAPF, tendinous arch Results: At 36 months after surgery the anatomical success rate (stage 0 or 1) was of the pelvic fascia; 93%.
  • Second and Third Generation Oral Fluoroquinolones

    Second and Third Generation Oral Fluoroquinolones

    Therapeutic Class Overview Second and Third Generation Oral Fluoroquinolones Therapeutic Class • Overview/Summary: The second and third generation quinolones are approved to treat a variety of infections, including dermatologic, gastrointestinal, genitourinary, respiratory, as well as several miscellaneous infections.1-10 They are broad-spectrum agents that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis by blocking the actions of DNA gyrase and topoisomerase IV, which leads to bacterial cell death.11,12 The quinolones are most active against gram-negative bacilli and gram-negative cocci.12 Ciprofloxacin has the most potent activity against gram-negative bacteria. Norfloxacin, ciprofloxacin and ofloxacin have limited activity against streptococci and many anaerobes while levofloxacin and moxifloxacin have greater potency against gram-positive cocci, and moxifloxacin has enhanced activity against anaerobic bacteria.11-12 Gemifloxacin, levofloxacin and moxifloxacin are considered respiratory fluoroquinolones. They possess enhanced activity against Streptococcus pneumoniae while maintaining efficacy against Haemophilus influenzae, Moraxella catarrhalis and atypical pathogens. Resistance to the quinolones is increasing and cross-resistance among the various agents has been documented. Two mechanisms of bacterial resistance have been identified. These include mutations in chromosomal genes (DNA gyrase and/or topoisomerase IV) and altered drug permeability across the bacterial cell membranes.11-12 Clinical Guidelines support
  • A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of

    A TWO-YEAR RETROSPECTIVE ANALYSIS of ADVERSE DRUG REACTIONS with 5PSQ-031 FLUOROQUINOLONE and QUINOLONE ANTIBIOTICS 24Th Congress Of

    A TWO-YEAR RETROSPECTIVE ANALYSIS OF ADVERSE DRUG REACTIONS WITH 5PSQ-031 FLUOROQUINOLONE AND QUINOLONE ANTIBIOTICS 24th Congress of V. Borsi1, M. Del Lungo2, L. Giovannetti1, M.G. Lai1, M. Parrilli1 1 Azienda USL Toscana Centro, Pharmacovigilance Centre, Florence, Italy 2 Dept. of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), 27-29 March 2019 Section of Pharmacology and Toxicology , University of Florence, Italy BACKGROUND PURPOSE On 9 February 2017, the Pharmacovigilance Risk Assessment Committee (PRAC) initiated a review1 of disabling To review the adverse drugs and potentially long-lasting side effects reported with systemic and inhaled quinolone and fluoroquinolone reactions (ADRs) of antibiotics at the request of the German medicines authority (BfArM) following reports of long-lasting side effects systemic and inhaled in the national safety database and the published literature. fluoroquinolone and quinolone antibiotics that MATERIAL AND METHODS involved peripheral and central nervous system, Retrospective analysis of ADRs reported in our APVD involving ciprofloxacin, flumequine, levofloxacin, tendons, muscles and joints lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, cinoxacin, nalidixic acid, reported from our pipemidic given systemically (by mouth or injection). The period considered is September 2016 to September Pharmacovigilance 2018. Department (PVD). RESULTS 22 ADRs were reported in our PVD involving fluoroquinolone and quinolone antibiotics in the period considered and that affected peripheral or central nervous system, tendons, muscles and joints. The mean patient age was 67,3 years (range: 17-92 years). 63,7% of the ADRs reported were serious, of which 22,7% caused hospitalization and 4,5% caused persistent/severe disability. 81,8% of the ADRs were reported by a healthcare professional (physician, pharmacist or other) and 18,2% by patient or a non-healthcare professional.
  • Complications of Incontinence and Prolapse Surgery: Evaluation, Intervention, and Resolution—A Review from Both Specialties W42, 16 October 2012 14:00 - 18:00

    Complications of Incontinence and Prolapse Surgery: Evaluation, Intervention, and Resolution—A Review from Both Specialties W42, 16 October 2012 14:00 - 18:00

    Complications of Incontinence and Prolapse Surgery: Evaluation, Intervention, and Resolution—A Review from Both Specialties W42, 16 October 2012 14:00 - 18:00 Start End Topic Speakers 14:00 14:10 Introduction Howard Goldman 14:10 14:35 Complications of incontinence surgery (except Sandip Vasavada retention) 14:35 15:10 Retention/Voiding dysfunction after incontinence Roger Dmochowski surgery 15:10 15:30 Discussion All 15:30 16:00 Break None 16:00 16:35 Complications of prolapse surgery (except Howard Goldman dyspareunia) 16:35 17:00 Dyspareunia after pelvic floor surgery Tristi Muir 17:00 17:40 Discussion All 17:40 18:00 Questions All Aims of course/workshop This course will summarize both common and uncommon complications associated with standard and new technologies used for pelvic floor reconstruction and urinary incontinence therapy in women. The intent of this course is to present both the approach to evaluation and management of these complications from both the urologic and urogynecologic perspective of the combined faculty. The emphasis is on newer technologies and complications, both acute and chronic, which are associated with these various surgeries. The goal of this course will be to summarize, not only identification, but also evaluation and appropriate intervention, as well as patient counselling for these various complications. Educational Objectives This course will provide a detailed paradigm for avoiding, evaluating and managing complications of incontinence and prolapse surgery. Evidence continues to accrue in this area but it runs the spectrum from Level 1 to 5 with much being expert opinion. Unfortunately, very little cross comparison exists to support these differing interventions.
  • Pessary Information

    Pessary Information

    est Ridge obstetrics & gynecology, LLP 3101 West Ridge Road, Rochester, NY 14626 1682 Empire Boulevard, Webster, NY 14580 www.wrog.org Tel. (585) 225‐1580 Fax (585) 225‐2040 Tel. (585) 671‐6790 Fax (585) 671‐1931 USE OF THE PESSARY The pessary is one of the oldest medical devices available. Pessaries remain a useful device for the nonsurgical treatment of a number of gynecologic conditions including pelvic prolapse and stress urinary incontinence. Pelvic Support Defects The pelvic organs including the bladder, uterus, and rectum are held in place by several layers of muscles and strong tissues. Weaknesses in this tissue can lead to pelvic support defects, or prolapse. Multiple vaginal deliveries can weaken the tissues of the pelvic floor. Weakness of the pelvic floor is also more likely in women who have had a hysterectomy or other pelvic surgery, or in women who have conditions that involve repetitive bearing down, such as chronic constipation, chronic coughing or repetitive heavy lifting. Although surgical repair of certain pelvic support defects offers a more permanent solution, some patients may elect to use a pessary as a very reasonable treatment option. Classification of Uterine Prolapse: Uterine prolapse is classified by degree. In first‐degree uterine prolapse, the cervix drops to just above the opening of the vagina. In third‐degree prolapse, or procidentia, the entire uterus is outside of the vaginal opening. Uterine prolapse can be associated with incontinence. Types of Vaginal Prolapse: . Cystocele ‐ refers to the bladder falling down . Rectocele ‐ refers to the rectum falling down . Enterocele ‐ refers to the small intestines falling down .
  • Nitrofurantoin Administration for the Prevention of Short-Term Catheter

    Nitrofurantoin Administration for the Prevention of Short-Term Catheter

    Study Title: Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial ClinicalTrials.gov ID: NCT03287089 Date: July 6, 2018 STUDY OBJECTIVES Primary Objective To evaluate the efficacy of administration of nitrofurantoin prophylaxis after catheter discontinuation for the prevention of catheter-associated urinary tract infections in patients with postoperative short-term catheterization following pelvic reconstructive surgery. The primary outcome will be the treatment of clinically suspected and/or culture-proven UTI within 30 days of surgery. Secondary Objectives 1. To evaluate adverse outcomes related to study medications in each group 2. To evaluate medication compliance BACKGROUND Urinary tract infections (UTI) are the most common hospital-acquired infections, accounting for nearly 30% of cases of nosocomial infections and affecting nearly 1 million people per year.1-3 They account for nearly 8.1 million visits to health care providers and cost an estimated $1.6 billion a year in the United States alone.3,4 Following pelvic reconstructive and urinary incontinence surgery, UTIs are one of the most common complications.4,5 The baseline risk of UTI associated with pelvic floor surgery ranges between 5-35%, increasing greatly with catheterization.3 In women who are undergoing surgery for urinary incontinence, the risk of UTI ranges between 8.9% to 34%.4,6,7 Risk factors for urinary tract infections in women undergoing pelvic floor
  • Bacterial Prostatitis

    Bacterial Prostatitis

    REVIEW CURRENT OPINION Bacterial prostatitis Bradley C. Gill a,b and Daniel A. Shoskesa,b Purpose of review The review provides the infectious disease community with a urologic perspective on bacterial prostatitis. Specifically, the article briefly reviews the categorization of prostatitis by type and provides a distillation of new findings published on bacterial prostatitis over the past year. It also highlights key points from the established literature. Recent findings Cross-sectional prostate imaging is becoming more common and may lead to more incidental diagnoses of acute bacterial prostatitis. As drug resistance remains problematic in this condition, the reemergence of older antibiotics such as fosfomycin, has proven beneficial. With regard to chronic bacterial prostatitis, no clear clinical risk factors emerged in a large epidemiological study. However, bacterial biofilm formation has been associated with more severe cases. Surgery has a limited role in bacterial prostatitis and should be reserved for draining of a prostatic abscess or the removal of infected prostatic stones. Summary Prostatitis remains a common and bothersome clinical condition. Antibiotic therapy remains the basis of treatment for both acute and chronic bacterial prostatitis. Further research into improving prostatitis treatment is indicated. Keywords acute bacterial prostatitis, bacterial prostatitis, category I prostatitis, category II prostatitis, chronic bacterial prostatitis, male pelvic pain INTRODUCTION and August 2015 were identified among the first Prostatitis is a bothersome condition but carries 600 search results. The titles of English language potential for serious morbidity from sepsis, abscess, articles were examined and those pertaining to non- or fistula if insufficiently managed. Nearly one in six bacterial prostatitis, chronic pelvic pain, and animal men report a history of prostatitis, resulting in over or basic science models were excluded.
  • Legacy Health

    Legacy Health

    Legacy Health Co-Management and Referral Guidelines Management of Pelvic Floor Dysfunction Phone: 503-413-3707 Legacy Physical Therapy Fax: 503-413-1504 Introduction After appropriate evaluation by your care providers, patients may be referred to pelvic floor physical therapy for management of pelvic floor muscle dysfunctions/pain, incontinence of urine or fecal matter, pelvic floor/girdle physical therapy. • Hypertonic pelvic floor dysfunction — vaginismus, dyspareunia, levator ani syndrome • Hypotonic pelvic floor muscles — organ prolapse, rectus diastasis • Continence issues after abdominal surgeries in male and female (prostate or hysterectomies), overactive bladder • Endometriosis, pelvic pain • Chronic constipation Evaluation Evaluation and A careful history and evaluation/physical exam will be performed to assess the origin and functional Management limitations of the patient. Muscle tone assessment, organ mobility, scar tissue mobility, bladder and/or bowel diary Treatment Strengthening or down-training PF muscles, with or without biofeedback, manual therapy, scar tissue release, electrical stimulation, trigger point release, visceral and myofascial mobilization, body mechanics and core stabilization. Duration One to six 60-minute visits with the physical therapist When to refer Refer when pain is limiting normal activities of daily living, if patient is not able to get to the bathroom dry, if sexual activity is painful (although dyspareunia alone is often not covered by insurance) Commonly referred ICD10 codes and descriptors for PT diagnoses R10.9 Abdominal pain K59.4 Anal spasm/proctalgia fugax R39.89 Bladder pain M53.3 Coccygodynia K59.00 Constipation, unspecified N81.10 Cystocele, unspecified (prolapse of anterior vaginal wall NOS) M62.0 Diastasis rectus post-partum N94.1 Dyspareunia — excludes psychogenic dyspareunia (F52.6).
  • Computational Antibiotics Book

    Computational Antibiotics Book

    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
  • Pelvic Floor Ultrasound in Prolapse: What's in It for the Surgeon?

    Pelvic Floor Ultrasound in Prolapse: What's in It for the Surgeon?

    Int Urogynecol J (2011) 22:1221–1232 DOI 10.1007/s00192-011-1459-3 REVIEW ARTICLE Pelvic floor ultrasound in prolapse: what’s in it for the surgeon? Hans Peter Dietz Received: 1 March 2011 /Accepted: 10 May 2011 /Published online: 9 June 2011 # The International Urogynecological Association 2011 Abstract Pelvic reconstructive surgeons have suspected technique became an obvious alternative, whether via the for over a century that childbirth-related trauma plays a transperineal [4, 5] (see Fig. 1) or the vaginal route [6]. major role in the aetiology of female pelvic organ prolapse. More recently, magnetic resonance imaging has also Modern imaging has recently allowed us to define and developed as an option [7], although the difficulty of reliably diagnose some of this trauma. As a result, imaging obtaining functional information, and cost and access is becoming increasingly important, since it allows us to problems, have hampered its general acceptance. identify patients at high risk of recurrence, and to define Clinical examination techniques, in particular if the underlying problems rather than just surface anatomy. examiner is insufficiently aware of their inherent short- Ultrasound is the most appropriate form of imaging in comings, are rather inadequate tools with which to assess urogynecology for reasons of cost, access and performance, pelvic floor function and anatomy. This is true even if one and due to the fact that it provides information in real time. uses the most sophisticated system currently available, the I will outline the main uses of this technology in pelvic prolapse quantification system of the International Conti- reconstructive surgery and focus on areas in which the nence Society (ICS Pelvic Organ Prolapse Quantification benefit to patients and clinicians is most evident.
  • The Effects of a Life-Stress Interview for Women with Chronic Urogenital Pain: a Randomized Trial" (2016)

    The Effects of a Life-Stress Interview for Women with Chronic Urogenital Pain: a Randomized Trial" (2016)

    Wayne State University Wayne State University Dissertations 1-1-2016 The ffecE ts Of A Life-Stress Interview For Women With Chronic Urogenital Pain: A Randomized Trial Jennifer Carty Wayne State University, Follow this and additional works at: http://digitalcommons.wayne.edu/oa_dissertations Part of the Clinical Psychology Commons Recommended Citation Carty, Jennifer, "The Effects Of A Life-Stress Interview For Women With Chronic Urogenital Pain: A Randomized Trial" (2016). Wayne State University Dissertations. Paper 1521. This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. THE EFFECTS OF A LIFE-STRESS INTERVIEW FOR WOMEN WITH CHORNIC UROGENITAL PAIN: A RANDOMIZED TRAIL by JENNIFER N. CARTY DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2016 MAJOR: PSYCHOLOGY (Clinical) Approved By: ______________________________ Advisor Date ______________________________ ______________________________ ______________________________ ACKNOWLEDGEMENTS I am immensely grateful to many people for their contributions to this project and my professional and personal development. First, I would like to thank my advisor, Dr. Mark Lumley, for his guidance and support in the development of this project, and for both encouraging and challenging me throughout my academic career, for which I will always be grateful. I would also like to thank Dr. Janice Tomakowsky, Dr. Kenneth Peters, and the medical providers, physical therapists, and staff at the Women’s Urology Center at Beaumont Hospital for graciously allowing me to conduct this study at their clinic and with their patients.
  • Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics

    Disabling and Potentially Permanent Side Effects Lead to Suspension Or Restrictions of Quinolone and Fluoroquinolone Antibiotics

    16 November 2018 EMA/795349/2018 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics EMA has reviewed serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics given by mouth, injection or inhalation. The review incorporated the views of patients, healthcare professionals and academics presented at EMA’s public hearing on fluoroquinolone and quinolone antibiotics in June 2018. EMA’s human medicines committee (CHMP) has endorsed the recommendations of EMA’s safety committee (PRAC) and concluded that the marketing authorisation of medicines containing cinoxacin, flumequine, nalidixic acid, and pipemidic acid should be suspended. The CHMP confirmed that the use of the remaining fluoroquinolone antibiotics should be restricted. In addition, the prescribing information for healthcare professionals and information for patients will describe the disabling and potentially permanent side effects and advise patients to stop treatment with a fluoroquinolone antibiotic at the first sign of a side effect involving muscles, tendons or joints and the nervous system. Restrictions on the use of fluoroquinolone antibiotics will mean that they should not be used: • to treat infections that might get better without treatment or are not severe (such as throat infections); • to treat non-bacterial infections, e.g. non-bacterial (chronic) prostatitis; • for preventing traveller’s diarrhoea or recurring lower urinary tract infections (urine infections that do not extend beyond the bladder); • to treat mild or moderate bacterial infections unless other antibacterial medicines commonly recommended for these infections cannot be used. Importantly, fluoroquinolones should generally be avoided in patients who have previously had serious side effects with a fluoroquinolone or quinolone antibiotic.